natgillin/translations-raw huggingface dataset:
There was an increase in mucosal or cutaneous candidiasis, consistent with the mechanism of action, but the cases were mild or moderate in severity, non-serious, responsive to standard treatment and did not necessitate treatment discontinuation.
Uočeno je povećanje broja slučajeva mukozne ili kožne kandidijaze, što je u skladu s mehanizmom djelovanja, ali slučajevi su bili blage ili umjerene težine, nisu bili ozbiljni, odgovarali su na standardno liječenje te nisu zahtijevali prekid liječenja.
There was an increased incidence of cardiac toxicity, but these events were comparable in nature and severity to those reported from the lapatinib clinical programme (see section 4.4 – cardiac toxicity).
Incidencija kardiološke toksičnosti je bila povišena, no ti su događaji po prirodi i težini bili usporedivi s događajima prijavljenima u kliničkom programu lapatiniba (vidjeti dio 4.4. – kardiološka toksičnost).
There was an increased incidence of tumours (hepatocellular adenomas) in mice exposed for 2 years to high doses (> 75 times human exposure), but this was considered secondary to prasugrel-induced enzyme-induction.
Incidencija tumora (hepatocelularnih adenoma) bila je povećana u miševa koji su dvije godine bili izloženi visokim dozama (> 75 puta veća izloženost nego u ljudi), ali se to smatralo posljedicom enzimske indukcije izazvane prasugrelom.
There was brain penetration, with accumulation over time with repetitive treatment, and effective reduction of levels of phospho-S6, a downstream marker of mTORC1.
Došlo je do prodiranja u mozak, uz nakupljanje tijekom vremena uz višestruko liječenje, i učinkovitoga smanjenja razina fosfo-S6, biljega silaznog puta mTORC1.
There was continuous improvement up to 36 months in the clinical outcome measure KOOS (the Knee Injury and Osteoarthritis Outcome Score) in both treatment arms.
Došlo je i do kontinuiranog poboljšanja tijekom 36 mjeseci u mjeri kliničkog ishoda KOOS (rezultat mjerenja ishoda nakon oštećenja koljena i osteoartritisa; engl. the Knee Injury and Osteoarthritis Outcome Score) u obje liječene skupine.
There was evidence for a benefit of telmisartan compared to placebo in the pre-specified secondary composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.87 (95 % CI 0.76 - 1.00, p = 0.048)].
Dokazana je korist liječenja telmisartanom u usporedbi s placebom u prethodno određenom sekundarnom složenom ishodu od kardiovaskularne smrti, nefatalnog infarkta miokarda i nefatalnog moždanog udara [0,87 (95 % CI 0,76 – 1,00, p = 0,048)].
There was evidence for a benefit of telmisartan compared to placebo in the pre-specified secondary composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.87 (95 % CI 0.76 - 1.00, p = 0.048)].
Postojao je dokaz pozitivnih učinaka telmisartana u usporedbi s placebom u unaprijed određenom sekundarnom kompozitnom ishodu kardiovaskularne smrti, nefatalnog infarkta miokarda i nefatalnog moždanog udara [0,87 (95 % CI 0,76 – 1,00, p = 0,048) ].
There was evidence for a benefit of telmisartan compared to placebo in the pre-specified secondary composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.87 (95 % CI 0.76 - 1.00, p = 0.048)].
Postojao je dokaz pozitivnih učinaka telmisartana u usporedbi s placebom u unaprijed određenom sekundarnom kompozitnom ishodu kardiovaskularne smrti, nefatalnog infarkta miokarda i nefatalnog moždanog udara [0,87 (95 % CI 0,76 – 1,00, p = 0,048)].
There was evidence for a benefit of telmisartan compared to placebo in the pre-specified secondary composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.87 (95 % CI 0.76 - 1.00, p = 0.048)].
Postojao je dokaz pozitivnih učinaka telmisartana u usporedbi s placebom u unaprijed određenom sekundarnom kompozitnom ishodu kardiovaskularne smrti, nefatalnog infarkta miokarda i nefatalnog moždanog udara [0,87 (95 % CI 0,76 – 1.00, p = 0,048)].
There was evidence for a benefit of telmisartan compared to placebo in the pre-specified secondary composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.87 (95 % CI 0.76 - 1.00, p = 0.048)].
Postojao je dokaz pozitivnih učinaka telmisartana u usporedbi s placebom u unaprijed određenom sekundarnom kompozitnom ishodu kardiovaskularne smrti, nefatalnog infarkta miokarda i nefatalnog moždanog udara [0,87 (95% CI 0,76 – 1,00, p = 0,048)].
There was faster normalisation of corrected serum calcium at day 4 for 8 mg zoledronic acid and at day 7 for 4 mg and 8 mg zoledronic acid.
Bila je brža normalizacija korigiranog kalcija u serumu 4. dana kod doze zoledronatne kiseline od 4 mg i 7. dana kod doze zoledronatne kiseline od 4 i 8 mg.
There was faster normalisation of corrected serum calcium at day 4 for 8 mg zoledronic acid and at day 7 for 4 mg and 8 mg zoledronic acid.
Pronašla se brža normalizacija korigiranog kalcija u serumu 4. dana kod doze zoledronatne kiseline od 4 mg i 7. dana kod doze zoledronatne kiseline od 8 mg.
There was faster normalisation of corrected serum calcium at day 4 for zoledronic acid 8 mg and at day 7 for zoledronic acid 4 mg and 8 mg.
Pronašla se brža normalizacija korigiranog kalcija u serumu 4. dana kod doze zoledronatne kiseline od 4 mg i 7. dana kod doze zoledronatne kiseline od 8 mg.
There was high between- patient variability in plasma imatinib AUC levels after an oral dose.
Između bolesnika postojala je velika varijabilnost u AUC razinama imatiniba u plazmi nakon jedne oralne doze.
There was less hyperbilirubinaemia and jaundice in the unboosted REYATAZ group compared with the REYATAZ + ritonavir group (18 and 28 subjects, respectively).
U skupini liječenoj nepojačanim lijekom REYATAZ zabilježeno je manje slučajeva hiperbilirubinemije i žutice nego u skupini koja je primala REYATAZ + ritonavir (18 naspram 28 ispitanika).
There was less use of morphinic analgesic (p < 0.01), non-morphinic analgesics (p < 0.01), other disease-related medications (p = 0.06) and radiotherapy (p < 0.01) in patients treated with docetaxel at 75 mg/m² compared to those with BSC.
Manje su se davali morfinski analgetici (p<0,01), ne morfinski analgetici (p<0,01), ostali lijekovi povezani s bolesti (p=0,06) i radioterapija (p<0,01) bolesnicima koji su se liječili docetakselom 75 mg/m2 nego onima iz skupine BSC.
There was less use of morphinic analgesic (p < 0.01), non-morphinic analgesics (p < 0.01), other disease-related medications (p = 0.06) and radiotherapy (p < 0.01) in patients treated with docetaxel at 75 mg/m² compared to those with BSC.
Manje su se davali morfinski analgetici (p<0,01), nemorfinski analgetici (p<0,01), ostali lijekovi povezani s bolesti (p=0,06) i radioterapija (p<0,01) bolesnicima koji su se liječili docetakselom 75 mg/m2 nego onima iz skupine BSC.
There was less use of morphinic analgesic (p < 0.01), non-morphinic analgesics (p < 0.01), other disease-related medicinal products (p = 0.06) and radiotherapy (p < 0.01) in patients treated with docetaxel at 75 mg/m2 compared to those with BSC.
Manje su se davali morfinski analgetici (p<0,01), ne morfinski analgetici (p<0,01), ostali lijekovi povezani s bolesti (p=0,06) i radioterapija (p<0,01) bolesnicima koji su se liječili docetakselom 75 mg/m2 nego onima iz skupine BSC.
There was less use of morphinic analgesic (p < 0.01), non-morphinic analgesics (p < 0.01), other disease-related medicinal products (p = 0.06) and radiotherapy (p < 0.01) in patients treated with docetaxel at 75 mg/m² compared to those with BSC.
Manje su se davali morfinski analgetici (p<0,01), nemorfinski analgetici (p<0,01), ostali lijekovi povezani s bolešću (p=0,06) i radioterapija (p<0,01) bolesnicima koji su se liječili docetakselom 75 mg/m2 nego onima iz skupine BSC.
There was less use of morphinic analgesic (p <0.01), non-morphinic analgesics (p <0.01), other disease-related medicinal products (p = 0.06) and radiotherapy (p <0.01) in patients treated with docetaxel at 75 mg/m² compared to those with BSC.
Manje su se davali morfinski analgetici (p<0,01), ne morfinski analgetici (p<0,01), ostali lijekovi povezani s bolesti (p=0,06) i radioterapija (p<0,01) bolesnicima koji su se liječili docetakselom 75 mg/m2 nego onima iz skupine BSC.
There was less use of morphinic analgesic (p<0.01), non-morphinic analgesics (p<0.01), other disease related medications (p=0.06) and radiotherapy (p<0.01) in patients treated with docetaxel at 75 mg/m² compared to those with BSC.
Manje su se davali morfinski analgetici (p<0,01), ne morfinski analgetici (p<0,01), ostali lijekovi povezani s bolesti (p=0,06) i radioterapija (p<0,01) bolesnicima koji su se liječili docetakselom 75 mg/m2 nego onima iz skupine BSC.
There was less use of morphinic analgesic (p<0.01), non-morphinic analgesics (p<0.01), other disease related medications (p=0.06) and radiotherapy (p<0.01) in patients treated with docetaxel at 75 mg/m² compared to those with BSC.
Manje su se davali morfinski analgetici (p<0,01), nemorfinski analgetici (p<0,01), ostali lijekovi povezani s bolesti (p=0,06) i radioterapija (p<0,01) bolesnicima koji su se liječili docetakselom 75 mg/m2 nego onima iz skupine BSC.
There was limited exposure in patients over 55 years of age in clinical studies with daclizumab.
U kliničkim ispitivanjima s daklizumabom bila je ograničena izloženost u bolesnika starijih od 55 godina.
There was no accumulation of bimatoprost in the blood over time and the safety profile was similar in elderly and young patients.
Nije došlo do akumulacije bimatoprosta u krvi tijekom vremena, a sigurnosni profil bio je sličan kod starijih i mlađih bolesnika.
There was no apparent impact of the presence of anti-rituximab or anti-rHuPH20 antibodies on safety or efficacy (SABRINA).
Prisutnost antitijela na rituksimab ili rHuPH20 nije imala primjetan utjecaj na sigurnost ni djelotvornost [SABRINA].
There was no apparent relationship with respect to occurrence of adverse events in the clinical studies for patients receiving various categories of the most common concomitant medications.
U kliničkim studijama kod pacijenata koji su primali različite kategorije najčešćih kombinacija lijekova nije bilo očite povezanosti s pojavom štetnih događaja.
There was no association of the presence of anti-alemtuzumab or inhibitory anti-alemtuzumab antibodies with a reduction in efficacy, change in pharmacodynamics, or the occurrence of adverse reactions, including infusion associated reactions.
Nije zabilježena veza između prisutnosti protutijela na alemtuzumab ili inhibicijskih protutijela na alemtuzumab i smanjena djelotvornosti, promjene farmakodinamike ili pojave nuspojava, uključujući reakcije povezane s infuzijom.
There was no attenuation of the bronchodilator effect over time in the 6- and 12-month studies.
Nije bilo slabljenja bronhodilatacijskog učinka tijekom vremena u 6- i 12-mjesečnim ispitivanjima.
There was no change in the kinetics of imatinib on repeated dosing, and accumulation was 1.5–2.5-fold at steady state when dosed once daily.
Nije bilo promjene kinetike imatiniba nakon ponovljenog doziranja, a akumulacija je bila 1,5 do 2,5 puta veća u stanju dinamičke ravnoteže kada je lijek doziran jednom na dan.
There was no change in the kinetics of imatinib on repeated dosing, and accumulation was 1.5–2.5-fold at steady state when dosed once daily.
Nije bilo promjene kinetike imatiniba nakon ponovljenog doziranja, a akumulacija je bila 1,5-2,5 puta veća u stanju dinamičke ravnoteže kada je lijek doziran jednom na dan.
There was no clinically meaningful drug-drug interaction between ketoconazole and apremilast.
Nije bilo klinički značajne interakcije između ketokonazola i apremilasta.
There was no clinically meaningful effect of age on raltegravir pharmacokinetics over the age range studied (19 to 71 years, with few (8) subjects over the age of 65).
Dob nije imala klinički značajnog učinka na farmakokinetiku raltegravira u ispitanom rasponu od 19 do 71 godine uz nekoliko (8) ispitanika starijih od 65 godina.
There was no clinically relevant difference in pharmacokinetics of Levemir between older and young subjects.
Nisu utvrđene klinički značajne razlike u farmakokinetici lijeka Levemir između starijih i mlađih ispitanika.
There was no clinically relevant difference in pharmacokinetics of Levemir between subjects with renal or hepatic impairment and healthy subjects.
Nisu utvrđene klinički značajne razlike u farmakokinetici lijeka Levemir između ispitanika s oštećenjem bubrega ili jetre i zdravih ispitanika.
There was no consistent difference in mean Cmax between orodispersible tablets and film coated tablets.
Nije bilo dosljedne razlike u prosječnoj Cmax između raspadljivih tableta za usta i filmom obloženih tableta.
There was no consistent difference in mean Cmax between orodispersible tablets and film coated tablets.
Nije bilo dosljedne razlike u srednjoj vrijednosti Cmax između raspadljivih tableta za usta i filmom obloženih tableta.
There was no detectable plasma protein binding following administration of [14C]-migalastat hydrochloride in the concentration range between 1 and 100 M.
Nije bilo primijećeno vezanje na proteine plazme nakon primjene [14C]-migalastatklorida u rasponu koncentracija između 1 i 100 M.
There was no difference between ataluren 20-, 20-, 40 mg/kg and placebo.
Nije bilo razlike između atalurena 20-, 20-, 40 mg/kg i placeba.
There was no difference between the atosiban and beta- mimetic groups with regard to this parameter.
Nije bilo razlike između skupina s atosibanom i beta- mimeticima s obzirom na ovaj parametar.
There was no difference between the atosiban and beta-mimetic groups with regard to this parameter.
Nije bilo razlike između skupina s atosibanom i beta- mimeticima s obzirom na ovaj parametar.
There was no difference between the combination and the individual components in severity for any observed adverse reactions.
Nije postojala razlika između kombinacije i pojedinačnih sastavnica s obzirom na težinu bilo koje primijećene nuspojave.
There was no difference in the change from baseline in whole body BMD or BMC for rilpivirine compared with control, in the overall population or in those patients treated with a backbone regimen including tenofovir disoproxil fumarate.
Nije bilo razlike u promjeni vrijednosti BMD-a cijelog tijela ili BMC-a u odnosu na početne za rilpivirin u usporedbi s kontrolnom skupinom, u ukupnoj populaciji ili u pacijenata liječenih temeljnim režimom uključujući tenofovirdizoproksilfumarat.
There was no difference in the overall safety profile in patients regardless of the antibody status with the exception of an increase of the incidence of injection site reactions (4.7% in antibody-positive patients compared to 2.5% in antibody-negative patients during the entire treatment period).
Nisu primijećene razlike među bolesnicima u ukupnom profilu sigurnosti primjene, neovisno o statusu protutijela, izuzevši povećanu incidenciju reakcija na mjestu injekcije (u 4,7% bolesnika s pozitivnim protutijelima u usporedbi s 2,5% bolesnika s negativnim protutijelima tijekom čitavog razdoblja liječenja).
There was no difference in the overall safety profile in patients regardless of the antibody status with the exception of an increase of the incidence of injection site reactions (4.7%in antibody positive patients compared to 2.5% in antibody negative patients during the entire treatment period).
Nisu primijećene razlike među bolesnicima u ukupnom profilu sigurnosti primjene, neovisno o statusu protutijela, izuzevši povećanu incidenciju reakcija na mjestu injekcije (u 4,7% bolesnika s pozitivnim protutijelima u usporedbi s 2,5% bolesnika s negativnim protutijelima tijekom čitavog razdoblja liječenja).
There was no difference in the pharmacokinetic profile of alglucosidase alfa in these juvenile late- onset patients compared to infantile-onset patients.
U ovih mladih bolesnika s kasnim oblikom bolesti nije bilo razlike u farmakokinetičkom profilu alglukozidaze alfa u usporedbi s bolesnicima s infantilnim oblikom bolesti.
There was no drug-related increase in tumour incidence in male or female rats in any other organ.
Nije bilo povećanja incidencije tumora u muških ili ženskih štakora ni u kojem drugom organu povezanih s lijekom.
There was no effect of anti-ipilimumab antibodies on the CL of ipilimumab.
Protutijela na ipilimumab nisu utjecala na klirens ipilimumaba.
There was no effect of maternal treatment with bedaquiline at any dose level on sexual maturation, behavioural development, mating performance, fertility or reproductive capacity of the F1 generation animals.
Nije bilo učinaka na liječenje majke bedakilinom pri bilo kojoj dozi na spolno sazrijevanje, bihevioralni razvoj, sposobnost parenja, plodnost ili reproduktivni kapacitet F1 generacije životinja.
There was no effect on the clearance of safinamide in patients with PD receiving safinamide as adjunct to chronic L-dopa and/or DA-agonists and safinamide treatment did not change the pharmacokinetic profile of co-administered L-dopa.
Nije bilo učinka na klirens safinamida u bolesnika s PB-om koji su primali safinamid kao dodatak kroničnom liječenju L-dopom i/ili agonistima dopamina, a liječenje safinamidom nije promijenilo farmakokinetički profil zajedno primjenjivane L-dope.
There was no effect on the fertility of rats treated orally with amlodipine maleate (males for 64 days and females for 14 days prior to mating) at doses of up to 10 mg amlodipine/kg/day (about 10 times the maximum recommended human dose of 10 mg/day on an mg/m2 basis).
Nije bilo učinka na plodnost štakora oralno liječenih amlodipinmaleatom (mužjaci 64 dana i ženke 14 dana prije parenja) pri dozama do 10 mg amlodipin/kg/dan (oko 10 puta više od maksimalne preporučene doze za ljude od 10 mg/dan na mg/m2 baze).
There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m2 basis).
Nije bilo učinka na plodnost štakora koji su primali amlodipin (mužjaci 64 dana i ženke 14 dana prije parenja) pri dozama od najviše 10 mg/kg/dan (8 puta više* od najviše preporučene doze za ljude od 10 mg izražene u mg/m2).
There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m2 basis).
Nije bilo učinka na plodnost štakora koji su primali amlodipin (mužjaci 64 dana i ženke 14 dana prije parenja) pri dozama od najviše 10 mg/kg/dan (8 puta* više od najviše preporučene doze za ljude od 10 mg izražene u mg/m2).
There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m2 basis).
Nije bilo učinka na plodnost štakora liječeni amlodipinom (mužjaci 64 dana i ženke 14 dana prije parenja) pri dozama od 10 mg/kg/dan (8 puta više* od najviše preporučene doze za ljude od 10 mg izražene u mg/m2).
There was no effect on the R- warfarin pharmacokinetics or on coagulation.
Nije bilo nikakvog utjecaja na farmakokinetiku R- varfarina ili zgrušavanje.
There was no evidence for benefit on cardiovascular mortality (hazard ratio 1.03, 95 % CI 0.85 - 1.24).
Nije bilo dokaza pozitivnih učinaka na kardiovaskularnu smrtnost (omjer rizika 1,03, 95 % CI 0,85 – 1,24).
There was no evidence for benefit on cardiovascular mortality (hazard ratio 1.03, 95 % CI 0.85 - 1.24).
Nije bilo dokaza pozitivnih učinaka na kardiovaskularnu smrtnost (omjer rizika 1,03, 95% CI 0,85 – 1,24).
There was no evidence for benefit on cardiovascular mortality (hazard ratio 1.03, 95 % CI 0.85 - 1.24).
Nije dokazana korist u odnosu na kardiovaskularni mortalitet (omjer hazarda 1,03, 95 % CI 0,85 – 1,24).
There was no evidence for benefit on cardiovascular mortality (hazard ratio 1.03, 95 % CI 0.85 - 1.24).
Nije dokazana korist u odnosu na kardiovaskularni mortalitet (omjer rizika 1,03, 95 % CI 0,85 – 1,24).
There was no evidence for benefit on cardiovascular mortality (hazard ratio 1.03, 95 % CI 0.85 - 1.24).
Nije dokazana koristi u odnosu na kardiovaskularni mortalitet (omjer hazarda 1,03, 95 % CI 0,85 – 1,24).
There was no evidence for benefit on cardiovascular mortality (hazard ratio 1.03, 95 % CI 0.85 - 1.24).
Nije dokazana koristi u odnosu na kardiovaskularni mortalitet (omjer rizika 1,03, 95 % CI 0,85 – 1,24).
There was no evidence for gender, weight or BMI to influence the pharmacokinetics of vilanterol based on a population pharmacokinetic analysis in 856 subjects with asthma (500 females).
Na temelju farmakokinetičke analize podataka prikupljenih u 856 ispitanika s astmom (500 žena), nema dokaza da spol, tjelesna težina ili ITM utječu na farmakokinetiku vilanterola.
There was no evidence for serious adverse reaction caused by imiquimod in paediatric patients.
Nema dokaza o ozbiljnim nuspojavama pri primjeni imikvimoda u pedijatrijskoj populaciji.
There was no evidence for tachyphylaxis in the effect of ANORO over time.
Nije bilo znakova tahifilaksije na učinke lijeka ANORO tijekom vremena.
There was no evidence for tachyphylaxis in the effect of Incruse over time.
Nije bilo znakova tahifilaksije na učinke lijeka Incruse tijekom vremena.
There was no evidence for tachyphylaxis in the effect of LAVENTAIR over time.
Nije bilo znakova tahifilaksije na učinke lijeka LAVENTAIR tijekom vremena.
There was no evidence of adverse reactions of tafamidis on fertility, reproductive performance or mating behaviour in the rat at any dose level.
Nije bilo dokaza štetnih učinaka tafamidisa na plodnost, reproduktivnu uspješnost ili ponašanje u vrijeme parenja u štakora ni pri kojoj razini doze.
There was no evidence of an altered pharmacokinetic or safety profile with anti-pembrolizumab binding antibody development.
Nije bilo dokaza promjena farmakokinetičkog ili sigurnosnog profila kod razvoja protutijela na pembrolizumab.
There was no evidence of an increased risk of adverse outcomes in over 100 pregnancies that were followed in a prospective clinical study.
U prospektivnom kliničkom ispitivanju nije bilo dokaza o povećanom riziku od nuspojava u više od 100 praćenih trudnoća.
There was no evidence of carcinogenic effect when clopidogrel was administered for 78 weeks to mice and 104 weeks to rats when given at doses up to 77 mg/kg per day (representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day).
Nije bilo dokaza o karcinogenim učincima kad se klopidogrel davao miševima 78 tjedana i štakorima 104 tjedna u dozama do 77 mg/kg dnevno (što predstavlja najmanje 25 puta veću izloženost od one primijećene u ljudi kod primijenjene kliničke doze od 75 mg/dan primijenjene u ljudi).
There was no evidence of genotoxicity in in vitro assays (reverse bacterial mutagenesis [Ames] and human lymphocyte chromosome aberration assays) or in the in vivo rat bone marrow micronucleus assay.
Nisu pronađeni dokazi genotoksičnosti u testovima in vitro (test reverzne mutacije bakterija [Amesov test] i test kromosomske aberacije na ljudskim limfocitima) ni u mikronukleusnim testovima na koštanoj srži štakora in vivo.
There was no evidence of impaired fertility or decreased reproductive capacity in rats administered oral dosages of Emedastine difumarate of up to 30 mg/kg/day.
Nije bilo dokaza o negativnom učinku na plodnost ili smanjenoj reproduktivnoj sposobnosti kod štakora koji su oralno primali emedastindifumarat u dozama do 30 mg/kg/dan
There was no evidence of systemic accumulation of tacrolimus in patients (adults and children) treated for prolonged periods (up to one year) with tacrolimus ointment.
Nema dokaza sistemskog nakupljanja takrolimusa u bolesnika (odraslih i djece) liječenih tijekom duljeg razdoblja (do jedne godine) takrolimus mašću.
There was no evidence of teratogenic effects or foetotoxicity due to enoxaparin.
Nije bilo dokaza o teratogenom učinku ili fetotoksičnosti zbog enoksaparina.